Thrifty Banker
  • Politics
  • Business
  • World
  • Investing
  • Politics
  • Business
  • World
  • Investing

Thrifty Banker

Investing

Top 3 Canadian Biotech Stocks

by January 26, 2024
January 26, 2024
Top 3 Canadian Biotech Stocks

Canada’s biotech sector is home to companies pursuing cutting-edge therapies and medical technologies.

Looking ahead into 2024, some market participants expect to see more investor interest in biotech as a variety of trends take hold — those include a greater focus on personalized medicine, cancer immunotherapies and more.

Both TSX and TSXV stocks were considered, but no TSXV companies made the list this time.

1. Antibe Therapeutics (TSX:ATE)

Company Profile

Year-on-year gain: 41.79 percent; market cap: C$53.69 million; share price: C$0.95

Antibe Therapeutics is focused on developing treatments for chronic pain and inflammation. Its flagship product, otenaproxesul, is an alternative to opioids and has proven to be gentler on the gastrointestinal (GI) tract than other non-addictive, non-steroidal anti-inflammatory drugs, which have been shown to cause ulcers and GI bleeding after long use.

Antibe’s first clinical study on a new formulation of otenaproxesul concluded in November 2023. The company plans to expedite the drug development process by conducting a Phase II post-operative trial on patients recovering from surgical bunionectomies (removal of a bunion), after which it will meet with the US Food and Drug Administration (FDA) to lay the groundwork for a Phase III trial. Antibe has not yet released dates for these trials.

Another drug in Antibe’s pipeline is a non-addictive analgesic derived from ketoprofen. The company is also currently researching a therapeutic solution for inflammatory bowel disease.

2. Cardiol Therapeutics (TSX:CRDL)

Press ReleasesCompany Profile

Year-on-year gain: 40.2 percent; market cap: C$91.81 million; share price: C$1.43

Cardiol Therapeutics is a biopharma company that is developing innovative treatments for inflammation and fibrosis in cardiovascular conditions. Its research efforts are concentrated in three key areas: pericarditis, which is inflammation of the membrane surrounding the heart; myocarditis, which is inflammation of the heart muscle; and heart failure.

Cardiol is currently developing two therapies. Its lead candidate, CardiolRX, is geared at treating rare heart diseases. The company announced in early January that it has exceeded 50 percent of the enrollments required to proceed with Phase II ARCHER trials of CardiolRX for the treatment of acute myocarditis.

CRD-38, a drug formulation of cannabidiol, is currently being researched by the company for its efficacy in treating heart conditions subcutaneously.

3. Knight Therapeutics (TSX:GUD)

Company Profile

Year-on-year gain: 7.39 percent; market cap: C$587.55 million; share price:C$5.67

Knight Therapeutics is a specialty pharmaceutical company that is involved in the licensing, marketing and commercialization of drugs in Latin America, Europe and the Commonwealth of Independent States.

In December 2023, the company entered into a licensing agreement with Supernus Pharmaceuticals (NASDAQ:SUPN) to bring ADHD therapy Qelbree to Canada. The drug was approved by the FDA in 2021 and is currently undergoing additional Phase IV trials, with more set to commence in 2024. In a statement announcing the partnership, Knight CEO Samira Sakhia expressed her desire to see the drug approved and made available to Canadians dealing with ADHD.

More recently, Knight announced the launch of IMVEXXY, a treatment option for dyspareunia in postmenopausal women.

Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com
0
FacebookTwitterGoogle +Pinterest
previous post
Palladium Price Forecast: Top Trends That Will Affect Palladium in 2024
next post
German defense minister says country is not ready to defend itself against Russian threat

Related Posts

Top 5 Canadian Nickel Stocks of 2025

April 5, 2025

ARway.ai Releases SDK 3.0 Marking a Major Upgrade...

March 15, 2024

5 Top Weekly TSXV Stocks: Noram Lithium Keeps...

June 24, 2024

Klimat X

September 29, 2023

Feasibility Study Confirms Strong Case for Expansion

January 24, 2024

Canadian North Resources Receives Total Proceeds of $9,186,597...

January 17, 2024

David Erfle: Gold’s 2024 Price Potential, How Silver...

May 7, 2024

Development update – Collie graphite micronising facility

June 3, 2025

Editor’s Picks: Gold Price Touches US$3,500 in Volatile...

April 26, 2025

Could a BRICS Currency be Backed by Gold?

November 21, 2023

    Sign up for our newsletter to receive the latest insights, updates, and exclusive content straight to your inbox! Whether it's industry news, expert advice, or inspiring stories, we bring you valuable information that you won't find anywhere else. Stay connected with us!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Popular

    • 1

      Top 10 Countries for Natural Gas Production (Updated 2024)

      April 6, 2024
    • 2

      Trump-era China sanctions ended by Biden may be revived under new House GOP bill

      June 27, 2024
    • 3

      Top 10 Uranium-producing Countries (Updated 2024)

      April 18, 2024
    • 4

      A GOP operative accused a monastery of voter fraud. Nuns fought back.

      January 3, 2025
    • 5

      Top 9 Nickel-producing Countries (Updated 2024)

      April 23, 2024
    • 6

      Australian abolitionist, Grace Forrest, receives coveted ‘Freedom from Fear’ award

      April 13, 2024
    • 7

      LME Sanctions on Russian Metal Push Copper, Nickel and Aluminum Prices Higher

      April 17, 2024

    Categories

    • Business (1,032)
    • Investing (2,050)
    • Politics (2,977)
    • Uncategorized (20)
    • World (3,351)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: thriftybanker.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 thriftybanker.com | All Rights Reserved